A strong correlation between CD133 expression and aggressive cellular behavior, including resistance to chemotherapy and radiotherapy, was also observed in hepatocellular carcinoma [6], colon cancers [7] and malignant gliomas [8,9], indicating that, regardless its role as a marker of stemness of tumor cells, CD133 may constitute a prognosticator for a number of different neoplasia. This evidence concerns the gene PROM1 and malignant glioma.